Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Approves BYSANTI for Bipolar I and Schizophrenia 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Xiaomi Shares Drop After SU7 Launch as Margin Concerns Weigh on Investors 
Jeff Bezos Eyes $100 Billion Fund to Transform Manufacturing With AI 
Elliott Investment Management Takes Activist Stake in Align Technology 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Malaysia Semiconductor Industry Eyes Helium Supply Risks Amid Middle East Conflict 
GE Vernova and Hitachi's $40 Billion SMR Investment Signals a New Era for U.S. Nuclear Energy 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
Xiaomi's AI Model "Hunter Alpha" Mistaken for DeepSeek's Next Release 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Virgin Australia Adjusts Fares Amid Rising Aviation Costs and Middle East Tensions 
Tesla FSD EU Approval Delayed to April 10 as RDW Completes Final Review 
Danish pharmaceutical giant Novo Nordisk has officially launched its once-daily Wegovy weight-loss pill in the United States, intensifying competition in the rapidly growing obesity drug market. The oral medication, approved by the U.S. Food and Drug Administration last month, will be available starting Monday and is aimed largely at self-paying patients seeking alternatives to injectable treatments.
Novo Nordisk is initially offering Wegovy pill doses of 1.5 milligrams and 4 milligrams at a price of $149 per month for cash-paying customers. However, pricing will rise over time, with the 4 mg dose increasing to $199 per month from April 15. Higher doses of 9 mg and a long-term maintenance dose of 25 mg will be priced at $299 per month. The pill contains semaglutide, the same active ingredient used in Novo’s injectable Wegovy and Ozempic, as well as its diabetes pill Rybelsus.
The launch is seen as a strategic move by Novo to regain momentum after profit warnings and share price declines last year, particularly as U.S. rival Eli Lilly continues to gain ground with its injectable obesity drug Zepbound. Lilly is also developing its own weight-loss pill, with an FDA decision expected in March. Investors reacted positively to Novo’s announcement, sending its Denmark-listed shares up 5% and U.S.-listed shares up 4.6%, while Lilly shares slipped.
Novo Nordisk is positioning the Wegovy pill as a more flexible and needle-free option, potentially attracting new consumers who are hesitant about injections. The company emphasized that success will depend heavily on attracting cash-paying customers, as insurance coverage for weight-loss drugs remains limited in the U.S.
The Wegovy pill will be distributed through major pharmacies such as CVS and Costco, along with telehealth platforms including Ro, LifeMD, WeightWatchers, GoodRx, and NovoCare Pharmacy. Telehealth stocks surged following the announcement, reflecting optimism around increased demand.
Novo also stated it has built sufficient inventory to avoid the supply shortages that previously plagued its injectable Wegovy rollout. Additionally, under an agreement with U.S. President Donald Trump, Novo and Eli Lilly will offer starter doses of their weight-loss pills at $149 per month to Medicare and Medicaid enrollees and through the upcoming TrumpRx direct-to-consumer platform.
